Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Hits Pause On M&A To See How US Tax Reform Plays

Executive Summary

CEO Ian Read indicated the company will wait to see if the US tax system is overhauled before completing any large-scale M&A, even as many investors are anxious to see Pfizer make an acquisition.


Related Content

Pfizer, Poised For A Tax Reform Windfall, Talks About Ways To Reinvest
Deal Watch: Takeda Continues Transaction Spree With Four More Deals
Is BMS The Must Have Immuno-Oncology Accessory Of The Season?
Pfizer's Xeljanz: The Slow Road To Blockbuster Status
Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal
Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer
Pharma Is Ready And Waiting For A Tax Holiday Under Trump
It's The End Of Pfizergan, So Pfizer Will Have To Grow It Alone


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts